New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For AMRN;VVUS From The Last 14 Days
Check below for free stories on AMRN;VVUS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 18, 2014
14:09 EDTVVUSVIVUS rallies, mean-reverting to intraday trend line
The shares have traded in an extremely wide range today on nearly 20 times daily average volume. An intraday trend line appears currently to be broken. That line is at $4.60 now, and projecting forward would be at the $4.80 area by the close. At the current price of $4.50, support is at $4.41 and then at $4.32.
12:45 EDTVVUSOn The Fly: Midday Wrap
Subscribe for More Information
09:36 EDTVVUSActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL YHOO TWTR VVUS RAD PWE WFM TSLA PIR SHLD
08:59 EDTVVUSOn The Fly: Pre-market Movers
Subscribe for More Information
06:05 EDTVVUSVIVUS, Auxilium announce FDA approval of STENDRA sNDA
VIVUS (VVUS) and Auxilium Pharmaceuticals (AUXL) announced that the FDA has approved a supplemental new drug application, or sNDA, for STENDRA. STENDRA is now the only FDA-approved erectile dysfunction, or ED, medication indicated to be taken as early as approximately 15 minutes before sexual activity. STENDRA is a prescription medication in a class of drugs known as phosphodiesterase type 5, or PDE5, inhibitors approved for the treatment of ED in men 18 years or older. STENDRA is available in multiple dosage strengths and may be taken with or without food and moderate alcohol consumption. In clinical studies, when compared to placebo, STENDRA helped more men achieve an erection in as early as approximately 15 minutes that lasted long enough to successfully complete sexual intercourse.
September 16, 2014
05:59 EDTAMRNAmarin to host conference call
Conference call to discuss its commitment to the REDUCE-IT study will be held on September 16 at 8 am. Webcast Link
05:34 EDTAMRNAmarin commits to completing REDUCE-IT cardiovascular outcomes study
Subscribe for More Information
September 12, 2014
16:20 EDTAMRNOn The Fly: Closing Wrap
Subscribe for More Information
14:59 EDTAMRNAmarin weakness an overreaction, says Citigroup
Subscribe for More Information
12:51 EDTAMRNOn The Fly: Midday Wrap
Stocks on Wall Street opened in negative territory and have remained there throughout the morning. The day’s economic data, including retail sales figures, a report on import prices, and business inventories data, were generally in line with expectations. The economic bright spot was the University of Michigan consumer confidence report which came in higher than expected. The market is on the verge of ending the week lower, which would be its first weekly loss in the last seven. ECONOMIC EVENTS: In the U.S., sales at retailers climbed 0.6% in August, matching expectations but also representing the fastest pace in four months. Retail sales growth for July was also revised upward to 0.3% from a prior estimate of having been flat. Import prices dropped 0.9% in August, while export prices slipped 0.5%. The University of Michigan preliminary consumer sentiment reading for for September rose to 84.6, beating expectations for it to be up more modestly to 83.3. Business inventories grew 0.4% in July, as expected. COMPANY NEWS: Shares of eBay (EBAY) were up more than 2% near noon after rumors circulated that Google (GOOG) may look to take a stake in the company. However, an eBay spokesperson denied the speculation, telling Reuters that the company has held "no conversations" with Google about acquiring a stake. MAJOR MOVERS: Among the notable gainers was digital marketing services company Conversant (CNVR), which soared 30% after Alliance Data Systems (ADS) agreed to acquire it for about $2.3B in cash and stock. Following last night's announcement of the deal, some Conversant peers rose as well, as Criteo (CRTO) gained almost 5% and TubeMogul (TUBE) rose 1%, while Alliance Data gained over 2%. Among the noteworthy losers was Amarin (AMRN), which dropped 22% after an office within the FDA denied the company's appeal of FDA's rescission of the ANCHOR clinical trial Special Protocol Assessment agreement. Also lower were shares of Ruckus Wireless (RKUS), which fell 5% after one analyst downgraded the shares and another initiated coverage of the stock with an Underweight rating. INDEXES: Near midday, the Dow was down 66.43, or 0.39%, to 16,982.57, the Nasdaq was down 19.83, or 0.43%, to 4,571.97, and the S&P 500 was down 10.28, or 0.51%, to 1,987.17.
10:10 EDTAMRNHigh option volume stocks
Subscribe for More Information
09:14 EDTAMRNOn The Fly: Pre-market Movers
Subscribe for More Information
09:04 EDTAMRNAmarin down 24.3% after FDA office denies appeal of ANCHOR rescission
09:03 EDTAMRNAmarin says FDA office denies appeal of ANCHOR rescission
Subscribe for More Information
09:02 EDTAMRNAmarin says FDA office denies appeal of ANCHOR rescission
September 11, 2014
12:42 EDTVVUSOrexigen falls after FDA requires warnings on Contrave label
Subscribe for More Information
10:59 EDTVVUSArena competition picks up after Contrave approval, says Piper Jaffray
Subscribe for More Information
08:01 EDTVVUSOrexigen Contrave could have stronger launch than peers, says Wells Fargo
After the FDA approved Orexigen's (OREX) Contrave as a treatment option for chronic weight management, Wells Fargo does not believe the label included any significant surprises. The firm thinks multiple factors increase the chances that Contrave's launch will be stronger than two other weight loss drugs that were launched in recent years by VIVUS and Arena Pharmaceuticals (ARNA). The firm keeps an Outperform rating on Orexigen.
September 10, 2014
14:17 EDTAMRNAmarin says Vascepa SPA rescission appeal on ANCHOR sNDA ongoing
Amarin says it is appealing to a higher level and if appeal is not successful that the company may pursue judicial relief under the First Amendment. Amarin says that the fight over Vascepa's sNDA for a mixed dyslipidemia indication is an "uphill battle," but the company believes patient care would benefit and that the company has valid legal, clinical and regulatory arguments. Information from slides for the company's presentation at the Rodman & Renshaw Global Investment conference.
September 9, 2014
12:46 EDTVVUSNovo Nordisk weight loss drug helped people get thinner, Bloomberg reports
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use